This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform

Transcription

1

2

3 This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include, but are not limited to, the design of clinical trials and expected timing for release of data; the anticipated clinical development milestones and other potential value drivers in the future; the expected benefits of the collaboration with Pfizer and Kite, the expanded capability of Sangamo s technologies; the research and development of novel gene-based therapies and the application of Sangamo s ZFP technology platform to specific human diseases; corporate partnerships; and the potential of Sangamo s genome editing technology to treat genetic diseases. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties. Factors that could cause actual results to differ include, but are not limited to, the dependence on the success of clinical trials of lead programs, the lengthy and uncertain regulatory approval process, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of Sangamo s therapeutics, uncertainties related to the initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of Sangamo s therapeutics, the reliance on partners and other third-parties to meet their obligations, and the ability to establish strategic partnerships. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its partners will be able to develop commercially viable gene-based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo s operations and business environments. These risks and uncertainties are described more fully in Sangamo s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this presentation are made as of the date hereof, and Sangamo undertakes no obligation to update such information except as required under applicable law. 3

4

5 5

6 6

7 Discovery Pre-clinical Phase I/II Clinical Phase III / Commercial 7

8 Therapeutic Area Research Preclinical Phase 1/2 Collaborator Next Milestone MPS I (SB-318) Initial Data: 2018 MPS II (SB-913) Initial Data: late summer 2018 Fabry Disease (ST-920) IND Filing: 2018 Hemophilia A (SB-525) Initial Data: late summer 2018 Hemophilia B (SB-FIX) UK Study Initiation: YE 18 Beta-thalassemia (ST-400) First Subject Enrolled: 1H 18 Sickle Cell Disease (BIVV-003) IND Filing: 2018 Tauopathies ALS/FTLD - C9ORF72 Huntington s Disease Autologous and Allogeneic CAR/TCR/NKR Undisclosed Targets HIV (T cell and Stem Cell)* *only advancing within industry / academic collaborations 8

9 9

10 Scope Economics Cell Therapy Oncology T cells and NK cells Ex Vivo genome editing (ZFNs and AAV) CARs, TCRs, and NKRs directed to tumor antigens Autologous and allogeneic products $150M $3.01B Upfront payment In potential R&D and sales-based milestones* Tiered royalties on net sales Solid and liquid tumor types * Aggregated across 10 or more products based on the achievement of certain research, development, regulatory and successful commercialization milestones 10

11 *FPI First patient in **SCD Sickle Cell Disease 11

12

13 Q Q YE 2017 $in MM, except per share data R&D G&A Operating expenses: $ M Total Operating Expenses Operating Loss (21.0) (16.8) (56.4) Net Loss (20.2) (16.6) (54.6) Net Loss per Share ($0.23) ($0.23) ($0.70) Ending Cash Balance $235M $133M $245M Cash and investments: >$485M 13

14 14

15 Therapeutic Area Research Preclinical Phase 1/2 Phase 3 MPS I (SB-318) MPS II (SB-913) Fabry Disease (ST-920) Tauopathies Undisclosed Targets o o o o o o o o 15

16 *Digital rendering of Sangamo cgmp facility 16

17

18 transgene liver cell DNA nucleus therapeutic gene liver cell AAV vectors 18

19 IND open Study initiated 8 sites active 4 subjects treated US EMA Orphan Drug designation Fast Track designation Orphan Medicinal Product designation 19

20 zinc finger nucleases transgene + albumin gene AAV vectors Strong albumin promoter H TG H transgene 20

21 INDs open Studies initiated 5 sites active 4 subjects treated US Orphan Drug designation Fast Track designation Rare Pediatric Disease designation 21

22 INDs open Studies initiated 6 sites active Multiple patients screening US Orphan Drug designation Fast Track designation Rare Pediatric Disease designation 22

23 IND open CTA granted Study initiated 4 sites active Plan to initiate U.K. study by YE 2018 US Orphan Drug designation Fast Track designation 23

24 BCL11A Enhancer Sequence Deletion BCL11A Enhancer Knocked Out 24

25 IND open Study initiated First subject enrolled expected 1H18 Leverages naturally-occurring, protective mechanism to increase fetal-hemoglobin Highly efficient, precise gene editing; low risk of insertional mutagenesis Non-viral delivery of ZFNs Potentially superior long-term safety profile 25

26

27 ZFN ZFN 27

28 ZFNs 28

29 Precision Efficiency Specificity Precision Efficiency Specificity Precision Efficiency Specificity 29

30 Liver-Based Expression of the Human Alpha-Galactosidase A Gene in a Murine Fabry Model Results in Continuous Therapeutic Levels of Enzyme Activity and Effective Substrate Reduction ZFN-Mediated In Vivo Genome Editing Results in Therapeutic Levels of α-galactosidase A and Effective Substrate Reduction in Fabry Knockout Mice Enhancing ZFN Expression Construct and Nuclease Activity Leads to Improvements of In Vivo Genome Editing Platform Global and Tunable Suppression of Zinc Finger Nuclease and ZFP-Transcription Factor Off-Target Activity via Discrete Framework Substitutions Non-Viral Delivery of ZFN mrna Enables Highly Efficient In Vivo Genome Editing of Multiple Therapeutic Gene Targets Highly Efficient and Specific Multiplexed Gene Editing in T Cells using Enhanced Zinc-Finger Nucleases (ZFNs) Enables Strategic Engineering of Allogeneic T Cell Immunotherapies Designed Zinc Finger Protein Transcription Factors for Single-Gene Regulation Throughout the Central Nervous System 30

31

32 32

33